Futura Medical specialises in the development and global commercialisation of innovative sexual health products, including lead product Eroxon®.
The company's core strength lies in its research, development and commercialisation of topically delivered gel formulations in sexual health products.
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the consumer healthcare company behind the erectile dysfunction gel Eroxon, has increased the size of its retail share offer after strong demand from investors.
The retail offer closed on Friday, having attracted applications well beyond the company's original target.
Futura had initially planned to raise £150,000 through the offer but upsized it to £200,000 following consultation with its advisers.
The retail offer forms part of a wider fundraising package that also includes a firm placing, a conditional placing and a conditional subscription.
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the sexual health group behind the Eroxon erectile dysfunction gel, has begun a formal process that could see the sale of the business, or its assets.
The move comes alongside a placing and subscription to raise approximately £1.6 million, which should fund it through to the conclusion of negotiations.
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) has passed a series of operational milestones across its sexual health portfolio as it repositions for growth following a strategic review.
The AIM-listed group behind Eroxon, the over-the-counter erectile dysfunction gel, appointed Market Performance Group as its new US commercial partner from 1 September, replacing Haleon after a two-month transition.
In investment circles, a company’s inflexion points - key developments that can drive growth - often signal a rise in stock price.
For Futura Medical PLC (AIM:FUM, OTC:FAMDF), several such events have unfolded recently, but its valuation seems slow to reflect them.
- Momentum builds for Eroxon; posts maiden profit
Shares in Futura Medical PLC (AIM:FUM, OTC:FAMDF) rose 7% in afternoon trading on Tuesday after the company reported better-than-expected full-year results and reiterated plans to expand its Eroxon product into 20 countries by the end of 2025.
Panmure Liberum highlighted the strong 2024 performance, which included a quadrupling of revenue to £13.9 million and a first-ever operating profit.
Futura Medical PLC (AIM:FUM, OTC:FAMDF) Head of R&D Ken James joined Steve Darling from Proactive to share the company’s latest developments in sexual health solutions. Futura’s flagship product, Eroxon, is a topical gel for erectile dysfunction (ED) that offers a rapid onset in under 10 minutes, setting it apart from traditional oral medications. “Eroxon has a very, very good side effect profile,” noted James, highlighting its suitability as an over-the-counter option for ED.
In response to consumer demand, Futura is developing an enhanced version called Eroxon Intense, catering to users seeking a stronger effect. This approach aligns with common consumer healthcare strategies, such as variations in pain relief formulations, allowing the company to meet diverse customer needs. In addition to Eroxon, Futura is working on an innovative product targeting female sexual dysfunction—a pressing yet often overlooked need, especially post-menopause, affecting up to 50% of women according to research. This female-focused product is showing promising early study results, and Futura plans to advance to broader trials and engage with the U.S. FDA for over-the-counter approval. With ongoing global partnerships and active engagement with regulatory authorities, Futura aims to establish a significant presence in both the male and female sexual health markets.
These advancements are backed by extensive research and a solid financial foundation, positioning Futura as a leader in addressing critical gaps in sexual health solutions.